Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths (PRISMA-1)

R

ROVI

Status and phase

Completed
Phase 1

Conditions

Schizophrenia
Schizoaffective Disorder

Treatments

Drug: Risperidone ISM 50 mg
Drug: Risperidone ISM 100 mg
Drug: Risperidone ISM 75 mg

Study type

Interventional

Funder types

Industry

Identifiers

NCT01788774
ROV-RISP-2011-01
2012-003303-35 (EudraCT Number)

Details and patient eligibility

About

This clinical trial is designed to evaluate different dosages of risperidone ISM, a new long-acting injectable form.

Full description

This clinical trial will try to characterize and document the pharmacokinetics of risperidone ISM in schizophrenic or schizoaffective patients after one intramuscular injection at different dose strengths.Likewise, the safety and tolerability of risperidone ISM will be evaluated in the above mentioned population. Following confirmation of eligibility and a washout period for study-prohibited drugs, a total of 33 subjects will be randomized in a 1:1:1 ratio to receive a single intramuscular (IM) injection of one of the following dosages of study drug: Group 1: 50 mg risperidone ISM Group 2: 75 mg risperidone ISM Group 3: 100 mg risperidone ISM Several blood samples for plasma pharmacokinetic (PK) assessments will be obtained pre-dose and post-dose. Safety assessments will be conducted at each pre-specified time points.

Enrollment

36 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Capable of providing informed consent.
  • Male or female aged ≥ 18 years to < 65 years
  • Current diagnosis of schizophrenia or schizoaffective disorder, according to the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders Clinical Trials (SCID-CT) or the DSM-IV-TR
  • Medically stable over the last month, and psychiatrically stable without significant symptom exacerbation over the last three months based on the investigator's judgment
  • Score of ≤ 4 (moderately ill) on the Clinical Global Impression - Severity of Illness (CGI-S)
  • If a sexually active female of childbearing potential, using a medically accepted contraceptive method.

Exclusion criteria

  • Presence of an uncontrolled, unstable, clinically significant medical condition that in the opinion of the investigator may interfere with the interpretation of safety and PK evaluations
  • If female, a positive serum pregnancy test, or planning to become pregnant between now and one month after the last dose of trial medication, or currently breastfeeding a child
  • History of neuroleptic malignant syndrome and current or past history of tardive dyskinesia
  • Positive urine drug/alcohol screen finding, unless the positive finding can be accounted for by documented prescription use.
  • In the investigator's opinion, at imminent risk of committing self-harm
  • Use of depot antipsychotics within the last three months
  • Receipt of any investigational drugs within the last three months
  • Current participation in any other clinical trial

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

36 participants in 3 patient groups

Risperidone ISM 50mg
Other group
Description:
Three different single doses will be evaluated
Treatment:
Drug: Risperidone ISM 50 mg
Risperidone ISM 75mg
Other group
Description:
Three different single doses will be evaluated
Treatment:
Drug: Risperidone ISM 75 mg
Risperidone ISM 100mg
Other group
Description:
Three different single doses will be evaluated
Treatment:
Drug: Risperidone ISM 100 mg

Trial contacts and locations

5

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems